Proteon logo     Print Page | Close Window

SEC Filings

10-Q
PROTEON THERAPEUTICS INC filed this Form 10-Q on 08/07/2017
Entire Document
 
 

 

Proteon Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

(Unaudited)

 

 

   Three Months Ended June 30,  Six Months Ended June 30,
   2017  2016  2017  2016
Operating expenses:                    
Research and development  $3,891   $5,241   $8,137   $9,590 
General and administrative   2,095    2,613    4,329    5,083 
Total operating expenses   5,986    7,854    12,466    14,673 
Loss from operations   (5,986)   (7,854)   (12,466)   (14,673)
Other income (expense):                    
Investment income   46    53    78    109 
Other income (expense), net   332    (104)   282    107 
Total other income  (expense)   378    (51)   360    216 
Net loss  $(5,608)  $(7,905)  $(12,106)  $(14,457)
Unrealized (loss) gain on available-for-sale investments   (7)   (2)   (7)   21 
Comprehensive loss  $(5,615)  $(7,907)  $(12,113)  $(14,436)
Net loss attributable to common stockholders  $(5,608)  $(7,905)  $(12,106)  $(14,457)
Net loss per share attributable to common stockholders - basic and diluted  $(0.33)  $(0.48)  $(0.72)  $(0.87)
Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted   17,207,672    16,561,239    16,923,515    16,534,413 
                     
Supplemental disclosure of stock-based compensation expense and loss from currency forward contracts:                    
Included in operating expenses, above, are the following amounts for non-cash stock based compensation expense:                    
Research and development  $308   $321   $606   $629 
General and administrative   559    625    1,106    1,183 
Total  $867   $946   $1,712   $1,812 
                     
Included in other (expense) income, net, above, are the following amounts from forward foreign currency contracts:                    
Realized losses from forward foreign currency contracts  $-   $(10)  $-   $(4)
Unrealized (losses) gains from forward foreign currency contracts   -    (53)   -    125 
Total  $-   $(63)  $-   $121 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 7